TY - JOUR AU - Yokota, T. AU - Ogawa, T. AU - Takahashi, S. AU - Okami, K. AU - Fujii, T. AU - Tanaka, K. AU - Iwae, S. AU - Ota, I. AU - Ueda, T. AU - Monden, N. AU - Matsuura, K. AU - Kojima, H. AU - Ueda, S. AU - Sasaki, K. AU - Fujimoto, Y. AU - Hasegawa, Y. AU - Beppu, T. AU - Nishimori, H. AU - Hirano, S. AU - Naka, Y. AU - Matsushima, Y. AU - Fujii, M. AU - Tahara, M. PY - 2017 DA - 2017/05/05 TI - Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study JO - BMC Cancer SP - 314 VL - 17 IS - 1 AB - Recent preclinical and phase I studies have reported that rebamipide decreased the severity of chemoradiotherapy-induced oral mucositis in patients with oral cancer. This placebo-controlled randomized phase II study assessed the clinical benefit of rebamipide in reducing the incidence of severe chemoradiotherapy-induced oral mucositis in patients with head and neck cancer (HNC). SN - 1471-2407 UR - https://doi.org/10.1186/s12885-017-3295-4 DO - 10.1186/s12885-017-3295-4 ID - Yokota2017 ER -